The Pipeline of Small Molecules
The Acute Coronary Syndrome (ACS) Market is heavily influenced by the development of new small molecule drugs. Small molecules are typically oral medications that are easy to manufacture and administer, making them a common choice for therapeutic development. The majority of marketed and pipeline drugs for ACS are small molecules, including various antiplatelet agents and enzyme inhibitors.
The focus of R&D in this area is on creating drugs with improved efficacy and safety profiles, such as those that offer potent platelet inhibition with a lower risk of bleeding. The development of new small molecules that target specific pathways in ACS pathophysiology is a key driver of market growth. This sustained focus on small molecule innovation confirms its central role in the Acute Coronary Syndrome Market.